Indication
Her2-Positive Locally Advanced Resectable Gastric Cancer
1 clinical trial
2 products
1 drug
Clinical trial
A Multicenter II Study to Compare KN026 and KN046 Versus Oxaliplatin, Capecitabine Combined KN026 and KN046 in Patients With HER2-positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.Status: Recruiting, Estimated PCD: 2025-09-01
Product
KN026Product
KN046Drug
XELOX